RESEARCH TRIANGLE PARK, N.C., Nov. 15 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced today that it has earned National Committee for Quality Assurance (NCQA) certification in disease management content and program design for a fifth program: Diabetes S.E.T. for Success(R).
GSK’s latest offering is designed to help healthcare organizations decrease the morbidity, mortality, complications and related costs associated with diabetes. Diabetes S.E.T. for Success includes tools to address the complexities of diabetes by:
-- Managing comorbidities -- Optimizing adherence -- Focusing on diversity -- Measuring outcomes
The program also helps healthcare professionals promote screening and detection, early treatment and more aggressive glycemic control in patients with or at risk for type 2 diabetes.
As with previous disease management submissions, GSK’s diabetes program was recognized by NCQA for its content and consistency with national practice guidelines and met 100% of NCQA’s rigorous requirements. GSK’s other NCQA- certified programs include:
ASK(SM) - Adherence Starts with Knowledge A medication adherence program that includes a survey and education materials for patients Asthma Focus(R) An award-winning program that provides a flexible framework to help improve asthma management and guideline compliance Migraine Matrix(R) Flexible tools that support initiatives to improve migraine care and outcomes. Restoring Stability(SM) An integrated approach to managing bipolar disorder
“Disease management offers tremendous promise for improving the care received by the chronically ill,” said NCQA President Margaret E. O’Kane. “By achieving NCQA Certification, an organization is showing that it is ready to provide specific services that can help fulfill that promise. It’s an accomplishment to be proud of.”
With certification, health plans have unbiased, third party confirmation from NCQA that GSK’s programs are evidence-based, well designed and appropriate for patients, practitioners and healthcare organizations. GSK does not directly provide disease management to patients, but offers these programs to healthcare organizations for them to implement.
“GlaxoSmithKline is committed to helping improve the quality of care for patients suffering from chronic conditions by developing evidence-based disease management and quality improvement programs,” said Tim Klapish, Executive Director, Medical Affairs Commercial Operations at GlaxoSmithKline. “NCQA certification validates our efforts and recognizes our dedication to quality and accountability.”
GlaxoSmithKline, one of the world’s leading research-based pharmaceutical and healthcare companies, is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
NCQA accredits and certifies a wide range of healthcare organizations and manages the evolution of HEDIS(R), the performance measurement tool used by more than 90 percent of the nation’s health plans.
HEDIS is a registered trademark of the National Committee for Quality Assurance (NCQA).
GlaxoSmithKline
CONTACT: Gaile Renegar, GlaxoSmithKline, +1-919-483-2839
Web site: http://www.gsk.com/
Company News On-Call: http://www.prnewswire.com/comp/801350.html/
